Document is current

Article History

Received: 19 March 2024

Revised: 7 January 2025

Accepted: 18 March 2025

First Online: 12 April 2025

Competing interests

: MS-C has given lectures in symposia sponsored by Almirall, Eli Lilly, Novo Nordisk, Roche Diagnostics, and Roche Farma; received consultancy fees (paid to the institution) from Roche Diagnostics; and served on advisory boards of Roche Diagnostics and Grifols. He was granted a project and is a site investigator of a clinical trial (funded to the institution) by Roche Diagnostics. In-kind support for research (to the institution) was received from ADx Neurosciences, Alamar Biosciences, Avid Radiopharmaceuticals, Eli Lilly, Fujirebio, Janssen Research & Development, and Roche Diagnostics. JLM is currently a full‑time employee of H. Lundbeck A/S and previously has served as a consultant or on advisory boards for the following for‑profit companies or has given lectures in symposia sponsored by the following for‑profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, and ProMIS Neurosciences. MSC has served as a consultant and at advisory boards for Roche Diagnostics International Ltd. and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U and Roche Farma, S.A. JDG receives research funding from Roche Diagnostics, F. Hoffmann-La Roche and GE Healthcare, has given lectures in symposia sponsored by Biogen, Esteve, Life Molecular Imaging and Philips and served in the Molecular Neuroimaging Scientific Board of Prothena Biosciences. GS-B has served as a consultant for Roche Farma, S.A. OGR receives research funding from F. Hoffmann-La Roche Ltd and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U. GK is a full‑time employee of Roche Diagnostics GmbH, Penzberg, Germany. CQ-R is a full‑time employee of Roche Diagnostics International Ltd, Rotkreuz, Switzerland.

: All participants were enrolled in the ALFA (ALzheimer and FAmilies) study (Clinicaltrials.gov Identifier: NCT01835717). The study was approved by the Independent Ethics Committee “Parc de Salut Mar,” Barcelona, and all participants gave written informed consent. All methods were performed in accordance with the relevant guidelines and regulations.